Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Feng Huang Tian Dan (Beijing) Technology Co., Ltd. is a Chinese biopharmaceutical company focused on the development of innovative traditional Chinese medicines (TCM). Established in 2023, the company operates as an affiliate of the Lihuayi Group and works in close collaboration with Shandong Fenghuang Pharmaceutical and the Beijing University of Traditional Chinese Medicine. Its lead candidate, Manpixiao Granules (慢痞消颗粒), is a novel herbal medicine currently in Phase II clinical trials for the treatment of chronic atrophic gastritis. The company aims to modernize traditional therapies to address unmet medical needs in digestive system disorders.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Feng Huang Tian Dan.